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Abstract 
Mannheimia (Pasteurella) haemolytica Al is the primary etiological agent of 
bovine pneumonic pasteurellosis or shipping fever. The primary goal of this research was 
to purify capsular polysaccharides, lipopolysaccharides, and outer membrane proteins of 
this organism and to test their strength as antigens against previously generated ascites-
form monoclonal antibodies. The secondary goal was to further purify and characterize 
the reactive antigen. Outer membrane proteins (OMPs) were the only P. haemoiytica 
surface product to show reactivity against 27-1 and 27-1-22 monoclonal antibodies using 
immunoblot and ELISA. The reactive OMP was found to be 18kD in size. In order to 
further characterize this OMP, affmity chromatography was used. However, these 
techniques were not successful in obtaining a pure sample of the 18kD OMP for use in N-
terminal amino acid sequencing. 
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Introduction 
Mannheimia (Pasteurella) haemolytica is the primary etiological agent of bovine 
pneumonic pasteurellosis. This disease, commonly referred to as shipping fever, affects 
cattle worldwide. In North America alone, it causes losses in the beef and dairy cattle 
industries of up to $800 million each year (44). Of primary concern in the cattle industry 
is the protection and nourishment of cattle until productive sale. Therefore, it is in the 
best interest of those within the industry to find ways to treat and prevent bovine 
pneumonic pasteurellosis. The disease is often fatal and develops most commonly in 
weaned and yearling cattle that have been transported recently (11). Characterized by 
severe, fibrinous pleuropneumonia, the disease is multifactorial and develops in the 
complex of bovine respiratory diseases. Development of the disease is usually associated 
with various combinations of stress along with infectious agents. The primary infectious 
agent of the disease is Mannheimia (Pasteurella) haemolytica. The stresses of cold 
weather, shipment, weaning, and overcrowding are most commonly associated with the 
disease (15,40). The major infectious stresses include viral agents such as bovine 
herpesvirus-l (BHV-l), parainfluenza-3 virus (PI-3), bovine viral diarrhea virus (BVD), 
infectious bovine rhinotracheitis virus (IBR), and respiratory syncytial virus (RSV). 
BHV-l alters bovine leukocyte functions, BVD causes immunosuppression, and PI-3 
increases susceptibility to Pasteurella-induced respiratory disease (5). Colonization of 
the lungs with pathogenic bacteria, primarily M haemolytica biotype A, serotype 1 (AI), 
is the final causative agent of pneumonic pasteurellosis. Mannheimia haemolytica A2 is 
almost always present in the nasal passages of healthy cattle, but it rarely causes 
pneumonic pasteurellosis. Al may also be present but not in high numbers (17). 
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However, once cattle are shipped, stressed, or infected with a respiratory virus, Al is the 
primary organism isolated from the bovine lung. Somehow, stress produces conditions 
favoring multiplication of Al in the upper respiratory tract (16). 
Mannheimia haemolytica is a gram negative, non-motile, facultatively anaerobic 
coccobacillus. It is a member of the family Pasteurellaceae Pohl. Once known as 
Pasteurella haemoiytica, A biotypes have now been regrouped into Mannheimia 
haemolytica based on I6s rRNA sequencing and DNA-DNA hybridization (2). 
However, for the sake of clarity, the Al serotype will be called Pasteurella haemolytica, 
with the understanding that the Al serotype is actually now called Mannheimia 
haemolytica. The outer surface of the bacterium is made up of potentially antigenic 
proteins, polysaccharides, and lipids. P. haemolytica also produces a leukotoxin 
(exotoxin) that is produced during logarithmic growth phase, a protease, a neuraminidase, 
a thick capsular polysaccharide, a lipopolysaccharide envelope (endotoxin), outer 
membrane proteins, and fimbriae (11). Pasteurella haemolytica forms small colonies that 
are white to light-gray in color on blood agar and 1 to 3 mm in size. The bacterium 
possesses a hemolytic activity producing a weak zone of p-hemolysis beneath the colony 
(44). In the genus Pasteurella, now separated into Pasteurella and Mannheimia, there 
are two distinct biotypes, characterized by their ability to ferment either arabinose or 
trehalose. A biotypes ferment arabinose, while T biotypes ferment trehalose (44). As 
previously stated, the primary cause of bovine pneumonic pasteurellosis is serotype AI. 
Four major virulence factors have been described. These include the fimbriae, capsular 
polysaccharide, lipopolysaccharide, and leukotoxin (9). 
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The fimbriae or pili allow the bacteria to adhere non-specifically to the surface 
of the upper respiratory tract using surface proteins called adhesins. As a virulence 
factor, the most important role offunbriae is to aid in colonization of the upper 
respiratory tract, which is a major step in the development of pneumonic pasteurellosis 
(9). Two types of fimbriae are produced: a large, rigid nonflexible structure of I2nm 
diameter and a small, thin flexible structure of 5nm diameter. Other serotypes of P. 
haemolytica are not known to produce fimbriae, identifying this as a virulence factor 
(45). 
During logarithmic growth, a capsular polysaccharide is produced. The quantity 
and thickness of capsule is often greater when grown within an infected calf. The capsule 
is also important for adherence to the alveolar and bronciolar surfaces and has a role in 
attracting neutrophils to the site of colonization. It may also inhibit phagocytosis and 
lysis via neutrophils and complement-mediated cell death (9). The basis for division of 
the serotypes of Pasteurella haemolytica is the immunological differences of the capsular 
polysaccharide of the different serotypes (3). The structure of the Al capsular 
polysaccharide is -7 3)-O-(2-acetarnido-2-deoxy-4-0-acetyl-p-D-mannopyranosyluronic 
acid-(l -7 4)-O-(2-acetarnido-2-deoxy-2-D-mannopyranose)-1 -7 (1). 
The lipopolysaccharide or endotoxin is the same as that produced by most gram-
negative bacteria. LPS is very important in the pathogenesis of the organism. In the 
bovine host, it is localized in neutrophils of the alveoli, interstitium, and capillary lumen, 
in macrophages of the intravasculature, intestines, and alveoli, in endothelial cells, and on 
epithelial cell surfaces (45). It is composed of a cytotoxic lipid A, a core 
oligosaccharide, and an antigen polysaccharide chain called the 0 antigen. It has been 
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demonstrated to cause direct cell-membrane damage upon bovine pulmonary epithelial 
cells, stimulation of leukocyte adherence and infiltration, and vascular damage through 
endothelial cell damage (9). The majority of the LPS produced by P. haemolytica is the 
smooth type. The lipid A portion has the capacity to activate serine proteases and 
therefore the first component of the classical complement pathway (45). The 0 antigen 
of the lipopolysaccharide has been characterized as a linear polymer ofa trisaccharide 
repeating unit having the structure ~ 3)-P-D-Gal p-(1 ~ 3)-P-D-Gal p Nac-(1 ~ 4)-P-D-
Gal p-( 1 ~. This same 0 antigen is expressed by many of the A serotypes of P. 
haemolytica (38). Furthermore, murine monoclonal antibodies have been used to 
demonstrate antigenic similarities among several serotypes of Pasteurella haemolytica 
(14). Competitive binding studies have shown the LPS to be a major antigenic 
determinant on the surface of the bacteria, but serum antibodies produced in calves after 
LPS injection did not seem significant for resistance to subsequent challenge exposure 
(10). When observed for its effects upon polymorphonuclear leukocytes (PMN), the LPS 
was not toxic. Phagocytosis of infecting cells decreased in the presence of high LPS 
concentrations (12). 
The most important factor for virulence of P. haemolytica is the leukotoxin 
(LKT). It is a chromosomally encoded exotoxin produced during the logarithmic growth 
phase and specific for leukocytes of ruminant animal species. Its role in virulence is 
primarily directed toward reducing phagocytosis and killing of the bacteria or by causing 
lysis of alveolar macrophages and neutrophils within the infected lung (9). It has a 
molecular weight of 105 kDa for its major protein component (6). LKT mainly acts upon 
susceptible cells by forming large transmembrane pores through which rapid influx of 
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Ca2+ may occur (7). Known to be encoded by a four-gene cluster of fktA, [ktE, [ktC, and 
[ktD, LktA is the protein ofLKT itself. LktC is required for activation ofLktA, while 
LktB and LktD are used for secretion (19). The leukotoxin is designated as an RTX 
(repeat toxin) (43). The [ktC gene mutants are equally capable of colonizing the upper 
respiratory tract of calves, but appear to be less virulent than wild-type strains under the 
same conditions (20). The epitopes involved in neutralization have also been 
characterized (22) along with a neutralizing monoclonal antibody to the toxin (18). 
The outer membrane proteins (OMP) of Pasteurella haemolytica Al are 
important in adhesion to the mucosal surface of the bovine upper respiratory tract (39). 
Antibodies to OMP have been demonstrated to be very important in establishing host 
immunity to pneumonic pasteurellosis in cattle (28). Major OMP of P. haemolytica have 
been shown to alter the activity of bovine neutrophils. This is important because 
neutrophils migrate to the lung within hours of the arrival of P. haemolytica. OMP also 
inhibit phagocytosis and intracellular killing, allowing the bacteria to proliferate within 
the lung (21). Pasteurella haemolytica also has three iron-regulated OMPs that are 
expressed only under iron-limited conditions. These three proteins are 71 , 77, and 
100kDa in size and show immuDogenicity using sera from calves previously infected 
with the organism. These proteins are only expressed in a low iron in vivo environment 
(25). Antibodies produced in calves against iron-regulated OMPs in conjunction with 
antibodies produced against other surface antigens provide enhanced immunity to 
challenge, especially using 70kDa and 77kDa iron-regulated OMPs (8). In another study 
a P. haemolytica Al mutant unable to produce three membrane lipoproteins (PlpA, PlpB, 
and PIpe) demonstrated increased susceptibility to bovine complement-mediated killing 
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when compared with wild-type P. haemolytica. It was concluded that if this mutant were 
able to elicit an effective immune response and experience effective clearance by the 
host, it may possess attenuation of virulence, making it a possible choice for a live 
vaccine (30). 
Three P. haemolytica genes (lppJ, /pp2, Ipp3) are known to encode 28-30kDa 
membrane proteins (31). Vaccination with the Lpp3 protein elicited the highest immune 
response and resistance to pneumonic pasteurellosis according to serum antibody levels 
(13). A major 41kDa surface-exposed OMP has also been isolated and characterized. Its 
N-tenninal sequence has shown strong homology to a 35kDa porin OMP of Pasteurella 
multocida, indicating that the 41kDa OMP is probably a porin OMP as well (23). 
Genetic and immunological analysis has been performed upon a 38kDa surface-exposed 
OMP as well. Called Lpp38, it is present in both inner and outer membrane fractions of 
the cell envelope. It is also recognized by sera from calves resistant to infection either by 
natural exposure or vaccination using outer membranes or live bacteria. It is therefore 
thought that this protein plays a role in the development of immunity to P. haemoiytica 
infection (35). Using the Sarkosyl extraction method, OMPs of30.5, 37, 38.5, 44.5, 49, 
62.5, and 82kDa were isolated. This same study compared OMPs of the various 
serotypes of P. haemolyfica and found expression of a 43kDa OMP in all of the 
serotypes. This 43kDa OMP was thought to be capable of eliciting cross-protective 
immunity among the various serotypes (27). Two OMPs of35kDa and 32kDa were 
identified as PomA and PomBo PomA demonstrated N-terminal sequence homology with 
the OmpA protein of Escherichia coli, but no homologous protein was found for PomBo 
Furthermore, sera from cattle vaccinated with live P. haemoiytica developed increased 
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serum antibodies to partially purified PomA and to purified PomA and PomB (24). In 
another study, three OMPs of31, 40, and 42 kDa were isolated and shown to be antigenic 
using sera from calves with prior exposure to P. haemolytica Al (4). Another 
lipoprotein, Plp4, 3IkDa in size was also shown to be capable of eliciting an immune 
response in cattle (32). In addition, 21 immunogenic, surface-exposed OMPs have been 
identified and recognized by bovine antisera from calves resistant to P. haemoiytica 
challenge by one of the following methods: natural exposure, vaccination with live P. 
haemoiytica, and vaccination with P. haemolytica OMPs. These OMPs were 110, 104, 
97,90, 76, 66, 62, 60, 56, 54,47, 39, 38, 36.5, 34, 32, 31.5, 28, 26, 24, and 22.5 kDa in 
size (34). 
As far as treatment of infected calves, antibiotics are available. One recent trial 
tested the efficacy of difloxacin and enrofloxacin, a novel fluoroquinolone, in calves 
experimentally infected with P. haemolytica. The study concluded that the two drugs 
were equally effective for treating the disease but may not eliminate P. haemolytica from 
the host (33). In view of the monetary repercussions and widespread nature of bovine 
pneumonic pasteurellosis, the most cost-effective way to at least reduce the occurrence of 
this disease is through the development and use of an effective vaccine. Many strategies 
have been employed in this effort. These include whole cell bacterin, culture filtrates, 
viral vaccines, and combined viraVbacterial vaccines containing P. haemolytica (11). 
Most studies have concluded that a mixture of leukotoxin and bacterial surface 
components in a subunit vaccine is most effective in eliciting a host immune response 
against P. haemolytica (11). Capsular polysaccharide vaccines are largely ineffective and 
actually cause disease development, indicating that CPS may playa large part in the 
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pathogenesis of the disease (37). Antibodies produced against LPS are also largely 
ineffective in providing protection against subsequent exposure to P. haemolyfica. The 
same study also indicated that passive immunization with antibodies to whole P. 
haemolytica or its LKT -containing supernatants provides protection against experimental 
challenge similar to that provided by immunization with the antigenic elements 
themselves (29). The use of OMP enriched fractions in a vaccine induced protective 
immunity against subsequent P. haemolytica challenge in calves (26). The efficacy of 
three commercial vaccines, One Shot, Presponse, and Once PMH, has also been 
evaluated. In these trials, One Shot was found to be most effective in reducing the 
formation of pneumonic lesions after experimental infection with P. haemolytica (42). 
In order to develop an effective vaccine to stimulate protective immunity in cattle, 
more study of possible subunit vaccines is required. The goal of this research project has 
been to use methods of cell fractionation to isolate the capsular polysaccharides, 
lipopolysaccharides, and outer membrane proteins of Pasteurella haemolytica Al and to 
test their strength as antigens using monoclonal antibodies produced in mice against live 
P. haemolytica injection. A further goal of this study was to attempt to characterize the 
surface antigen found to be the most antigenic. 
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Materials and Methods 
Bacterium 
Pasteurella (Mannheimia) haemolytica biotype A serotype 1 (isolate 88-1165), 
isolated from the lung of a pneumonic calf, was provided by Dr. Robert D. Walker 
(Michigan State University, East Lansing, MJ). The organism had been passed two times 
in calves by intrapulmonary inoculation, re-isolated, and stored in skim milk at -80 
degrees Celsius (C). In vitro passage of the organism was carried out at 37 C in brain 
heart infusion broth (BID, BBL, Cockeysville, MD). 
Cell Culture 
A hybridoma cell line previously generated from the fusion of mouse 
spleenocytes to SP2-0 cells was used in the generation of the 27-1-22 antibody in cell 
culture (47). The cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% fetal bovine serum (Atlanta Biologicals, Atlanta, GA), 2000 
units (U) penicillinl2 milligram (mg) streptomycin per liter of medium, 40 millimolar 
(mM) L-glutamine (psg: Sigma) and 0.2% sodium bicarbonate (NaHC03: Mallinckrodt, 
Paris, KY) at 37 C in an atmosphere of5% CO2 in the air. Cells were propagated by 
splitting 1: 1 0 into fresh medium every four days. 
Outer Membrane Protein Preparation 
The outer membrane proteins of P. haemolytica were isolated by a modification 
of the methods ofRapp, et af (45), Brennan, et af (33), and Squire, et af (45). 100 
microliters (fll) of frozen stock P. haemolytica in BID and glycerol were inoculated into 
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10 milliliters (ml) ofBHI broth and incubated overnight at 37 C in a shaking water bath 
(Orbit Environ-Shaker, Lab-Line Instruments Inc., Melrose Park, IL) at 225 revolutions 
per minute (rpm). SOO~1 of this overnight culture was then inoculated into SOml ofBHI 
broth. This was then placed in a shaking water bath at 37 C at 22Srpm for 4-6 hours, the 
predetermined time to reach logarithmic growth phase. The cells were then harvested by 
centrifuge at 14,SOO x gravity (g) for 20 minutes at 4 C. The supernatant was discarded 
and the pellet was resuspended in 20ml of 10 mM HEPES buffer (N-2-
Hydroxyethylpiperazine-N' -2-Ethanesulfonic acid, United States Biochemical 
Corporation, Fair Lawn, NJ, pH 7.4). Using a sonicator (Sonic Dismembrator, Fisher 
Scientific, Tustin, CA) set at SO% max output, the cells were disrupted with 3 to S bursts 
for 20 seconds each, with 20 second rests in between, while cooling the tube in an ice 
bath. Whole cells and insoluble debris were removed by centrifuge at 2S00 x g for 20 
minutes at 4 C. The supernatant was transferred to fresh centrifuge tubes to pellet the 
total membrane fraction at 100,000 x g for 60 minutes at 4 C. The supernatant was 
discarded, and the pellet was resuspended in 8ml of 1 % Sarkosyl (Fisher Biotech, Fair 
Lawn, NJ) and allowed to incubate for 30 minutes at room temperature to selectively 
solubilize the inner membrane. The outer membrane proteins were pelleted at 100,000 x 
g for 60 minutes at 4 C. After discarding the supernatant, the pellet was resuspended in 4 
ml of deionized water (dH20) and stored at 4 C until used. 
Lipopolysaccharide Preparation 
The lipopolysaccharide preparation was isolated according to the method of Staub 
(43). 100111 of frozen stock P. haemolytica in BHI and glycerol were inoculated into 10ml 
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ofBHI broth and incubated overnight at 37 C in water with shaking at 225 rpm. 500: I of 
this overnight culture was inoculated into 50ml ofBHI broth. This culture was placed in 
a shaking water bath at 37 C at 225rpm for 4-6 hours to reach logarithmic growth phase. 
The cells were then harvested by centrifugation at 7000 rpm for 30 minutes at 4 C. The 
whole cells were washed twice with a 0.85% saline solution at 7000 rpm for 30 minutes 
at 4 C. The cells were then weighed and suspended in a volume of 4 C dH20 equal to 
five times their wet weight. An equal volume of trichloroacetic acid (TCA) was then 
added, and the mixture was shaken. The mixture was then cooled in an ice bath for 3 
hours. After allowing the mixture to warm to room temperature, it was centrifuged at 
7000rpm for 30 minutes at 4 C. The pellet was discarded. The supernatant was then 
neutralized to pH 6.5, first with 1 molar (M) NaOH and then with O.IM NaOH. The 
supernatant was then cooled to 4 C in an ice bath. Precipitation was done by pouring the 
cold supernatant into 2 equal volumes of95% ethanol cooled to -10 to -15 C in an ice 
bath. It was allowed to stand at 4 C overnight in a sealed container. The mixture was 
then centrifuged at 4 C at 7000 rpm for 30 minutes. The pellet was dissolved in 10% of 
the original volume with dH20 and neutralized to pH 7. The solution was dialyzed using 
dialysis tubing with a molecular weight cutoff value of 12,000 to 14,000 (SpectraiPor, 
Spectrum, Gardena, CA) for 3 days at 4 C against 4 L of 0.1 M MgCl, changing the 
dialysis solution every 24 hours. The dialysis product was centrifuged at 27,000 x gat 
4 C for 30 minutes, and the pellet was discarded. The supernatant was then freeze-dried 
for 2 days. The [mal product was then stored at 4 C until ready for use. 
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Capsular Polysaccharide Preparation 
The capsular polysaccharide was prepared by the method of Adlam (1). IOOl-llof 
frozen stock P. haemolytica in Bill and glycerol were inoculated into 10mI of Bill broth 
and incubated overnight at 37 C in a shaking water bath at 225 rpm. 500lliofthis 
overnight culture was then inoculated into 50mI ofBHI broth. This was then placed in a 
shaking water bath at 37 C at 225rpm for 4-6 hours to reach logarithmic phase. The 
culture was then heated at 60°C for 1 hour and 0.2% formalin was added. The cells were 
removed by centrifugation at 9500 x g for 20 minutes at 4°C. The supernatant was 
retained and concentrated to 1/50 of the original volume using an Amicon <10,000 
molecular weight cut-off filter. Three volumes of methanol and sodium acetate were 
added to the concentrated supernatant. The precipitate formed was allowed to settle at 
4 C overnight and was discarded. The methanol supernatant was filtered using a 0.2 
micrometer (f!m) Millipore membrane filter. Three volumes of acetone were then added. 
The precipitate formed was allowed to settle and the supernatant was discarded. The 
precipitate was resuspended in dH20 and lyophilized in dry ice. 1 g of the lyophilized 
precipitate was dissolved in 1/10 saturated Sodium Acetate (NaOAc) (50ml) + 77% 
phenol (25ml) and shaken for about 2 minutes. The phases were then split by 
centrifuging at 13,500 x g for 1 hour at 4 C. The resultant phenol phase was re-extracted 
as above three times more with fresh NaOAc, and the phenol phase was discarded. The 
pooled aqueous phase was then dialysed against 4 liters (L) ofO.1M CaCh for 24 hours, 
changing the dialysis solution after 12 hours. The dialysed solution was centrifuged at 
100,000 x g for 3 hours at 4 C, and the ethanol supernatant was discarded. The 
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precipitate was washed in ethanol and frozen in dry ice. This frozen product was then 
lyophilized and stored at 4 C until used. 
Western Immunoblot 
Protein preparations were run on sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDSIP AGE) using a Mini Protean II gel apparatus (Bio-Rad). Stacking 
gels of 4 to 10% and separating gels of 10 to 18% (acrylamidelbisacrylamide 30:0:8; 
National Diagnostics, Atlanta, GA) were used. Protein preparations were adjusted to 
desired concentration in phosphate buffered saline (PBS), pH 7.4 and 2X sodium dodecyl 
sulfate (SDS), pH 6.8 sample buffer and electrophoresed from 120 to 240 minutes at a 
constant current of 14rnA. 
The SDSIP AGE gels were then soaked in protein transfer buffer consisting of 
0.025M tris base (PH 8.2; Sigma), 0.19M glycine (Fisher) and O.IM SDS. The proteins 
in the gel were transferred to Immobilon-P polyvinylidene difluoride (PVDF) membranes 
(Millipore) using a semi-dry protein transfer apparatus (Gelman) at 175 rnA for 2 hours. 
Vacant protein binding sites were then blocked using 3% Nonfat Dry Milk (Carnation 
Co., Los Angeles, CA) in tris-buffered saline (TBS) at 37 C, gentle agitation for 1.5 
hours. After two 15 minute rinse cycles in fresh TBS-0.05% Tween-20 (Sigma) at room 
temperature, proteins of interest were bound using primary antibody of2% ascites-form 
antibody in TBS. This primary antibody solution was added to the membrane under 
gentle shaking for 1.5 hours at 37 C or overnight at room temperature. The membrane 
was then rinsed with fresh TBS-0.05% Tween-20 as outlined above. Protein bands 
bound by the specific antibody were visualized by adding a 1 :2000 solution of 
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horseradish peroxidase-conjugated protein G (HRP-protein G) prepared in TBS. Protein 
G bound to the heavy chain of immunoglobulin (antibody) molecules. The membrane 
was soaked in this solution with gentle shaking for 1.5 hours at 37 C. Rinsing was then 
done as stated above. A developing solution was prepared using a mixture ofBiorad 
HRP color development reagent, methanol, TBS, and 30% H20 2 . After about 30 minutes 
of gentle shaking, the development was terminated by washing the membrane in dH20, 
leaving insoluble black color bands where the HRP-protein G had bound to antibody 
molecules. Since the antibody bound to a specific antigen protein band, this process 
visualized and identified proteins to which the antibody reacted specifically. 
SDS-PAGE Coomassie Blue Staining 
To visualize proteins in the SDSIPAGE gel or PVDF membrane, the membrane or 
gel was soaked in 0.50% Coomassie Brilliant Blue R-250 (BioRad) in 5% methanol and 
7.5% acetic acid (Mallinckrodt) at room temperature until the gel or membrane was 
saturated with staining solution. The membrane or gel was then destained by soaking in 
40% methanol and 10% acetic acid in dH20 at room temperature until stained protein 
bands could be visualized upon the membrane or gel. 
Dot-Blot Test 
The dot-blot apparatus was set up using the same PVDF membrane used for 
Western Blots. 1110 dilutions of whole washed P. haemoiytica cells, LPS, CPS, OMP, 
leukotoxin, and 2% wt bovine serum albumin (BSA) in dH20 were loaded onto the 
apparatus and applied to the membrane using vacuum force for 2 minutes. The 
16 
membrane was then removed in four segments and treated with four primary antibodies 
ofascites-fonn monoclonal antibodies 27-1,27-1-22,22-2-87, and 27-18-103. The 
incubation time, secondary antibody application, and development were the same as 
described for the Western Blot protocol. 
Direct ELISA 
Using Falcon Pro-Bind 96-well flat bottom microtiter plate (Falcon, Beckton-
Dickinson, Franklin Lakes, N.J), 50f,!1 of each (whole cells, CPS (1/1 0 dilution), LPS 
(1/10 dilution), OMP (1/10 dilution), leukotoxin (2%), and BSA (2%» were applied and 
the plate was allowed to dry overnight. The plate was then blocked with 2% gelatin in 
dH20 at 200f,!i per well. The plate was covered and placed in a humid chamber to rotate 
at 37 C for 1.5 hours. It was then rinsed three times with TBS-O.OS% Tween-20. The 
plate was then divided into four sections and treated with primary antibody of2% crude 
ascites of27-1, 27-1-22,22-2-87, and 27-18-103 in respective sections ofthe microtiter 
plate at 50f,!1 per well. The plate was placed in the humid chamber to rotate at 37 C for 
1.S hours and then rinsed as before. Secondary antibody of 1 :2000 HRP conjugated 
protein G was then added to each gel at SOf,!1 per well, and the plate was then placed in 
the humid chamber to rotate at 37 C for 1.S hours. Rinsing followed as before and 
development of the assay was done using the previously described ZYMED kit (ABTS 
for HRP) for 30 minutes in the dark. After development, the plate was analyzed using a 
microtiter plate reader (Spectra-Max 340, Molecular Devices) set to read solution 
absorbance at 405 nanometers (nm) light wavelength (~05). Wells with higher 
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absorbance indicated higher concentrations of binding of the primary ascites antibodies to 
the tested antigen. 
Large Scale Preparation of Antibody Supernatant 
From a viable hybridoma cell culture of the 27-1-22 antibody, 6 ml of the cell 
culture contained in a 25 cm2 small flask were transferred to a 75 cm2 flask containing 
23mL of fresh DMEM media described earlier. After 24-48 hours of incubation, 30ml of 
fresh media were added. When the ceUs were then ready to be supplied with fresh media, 
the content of the 75 cm2 was transferred to a roller bottle containing 90ml of fresh 
media. Fresh media was subsequently added in 150ml increments each day for 3 days 
followed by 300ml increments for 2 days, followed by a 600ml fresh media addition on 
the following day. After this culture had reached the desired growth level, turning the 
media a bright orange color, the supernatant medium was harvested by transfer to 
centrifuge bottles with subsequent centrifugation at 3000 rpm for 15 minutes at 4 C. The 
supernatant medium was then filtered using Millipore 0.021lm Stericaps (Millipore 
Corporation, Bedford, MA). The filtered supernatant was stored at 4 C and used within 
48 hours. 
Purification of27-1-22 antibody 
The 27-1-22 antibody was purified by affmity chromatography using Rat-Anti 
Mouse Kappa light chain antibodies bound to Sepharose 4B (ZYMED). This sepharose 
matrix was packed in a BioRad affmity chromatograpy column according to 
manufacturer's directions. All work with the affmity column was perfomed at 4 C. First, 
18 
PBS was passed through the column for three complete bed volumes. The supernatant 
containing the antibody was passed through the column using a peristaltic pump 
(Pharmacia, Piscataway, NJ) in lL increments. After each liter, three column volumes of 
PBS were passed through the column to remove unbound antibody. Next, an eluting 
buffer ofO.1M Sodium Citrate, pH 2.6 was passed through the column and collected in 
1m! increments, each combined with 6 drops of neutralizing buffer (1M Potassium 
phosphate dibasic, pH 8.0). Each aliquot was then analyzed at A280, and those with 
absorbance readings of 0.1 or greater were reserved and stored at 4 C for future use. 
Purification of monoclonal antibody 27-1-22 
Using a Gamma bind column (protein G column) (Zymed, San Franscisco, CA) 
and the following protocol, the monoclonal antibody 27-1-22 was purified from ascites 
fluid and concentrated. The column was first equilibrated with 10 column volumes of 
washing/binding buffer (O.OIM Sodium phosphate, pH 7.0 and 0.15M Sodium chloride). 
The ascites sample volume of 10ml was then allowed to pass through the column to allow 
affmity binding of antibodies to the bound protein G. Next, the column was washed 
using the washing/binding buffer for about 10 column bed volumes to rinse unbound 
ascites proteins. The bound antibodies were then eluted from the column using eluting 
buffer (0.5M Ammonium acetate, pH 3.0). The eluent was neutralized with 0.55m1 of 
neutralizing buffer (lM Tris, pH 9.5) per mI of eluted fluid. Eluted samples with A280 of 
0.1 or greater were reserved for future use. 
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Purification of Antigenic 18kD Outer membrane protein by EAR Sepharose Method 
An affmity chromatography column was constructed using EAR Sepharose 4B 
(Pharmacia) according to the directions provided by the manufacturer using N-ethyl-N'-
(3-dimethyl-aminopropyl) carbodiimide hydrochloride (EDe) to couple the antibody or 
asciety to the matrix. Two columns were constructed; one with 27-1-22 purified antibody 
produced by the hybridoma cells and one with 27-1-22 monoclonal antibody purified 
from crude ascites. Three bed volumes of PBS were passed over each column to pack the 
matrix. This was followed by three bed volumes of binding buffer (lOmM phosphate, pH 
6.8). Sterile-filtered outer membrane protein preparations were then passed over the 
column and allowed to bind. Three bed volumes of PBS were then passed over the 
column to remove any unbound P. haemolytica outer membrane proteins. The following 
buffers were used in the same fashion as the previously mentioned affmity 
chromatography methods: eluting buffer (I OOmM glycine, pH 2.5) and neutralizing 
buffer (l/20 vol 1M phosphate, pH 8.0). Elutions were taken as before and analyzed at 
A2so. 
Purification of 18kD Outer Membrane Protein by Kappa Light Chain Column Method 
The previously constructed Kappa Light Chain column was used at 4 C. First 
PBS was passed through the column for three complete bed volumes. The supernatant 
containing the antibody was passed through the column using a peristaltic pump in lL 
increments. After binding the antibody the column, the unbound antibody was removed 
from the column using three complete volumes of PBS passed through the column. Next, 
a dilute sample of purified outer membrane protein in dH20 (0.01255 mg/ml) was passed 
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through the column to allow the 18kD antigenic protein to bind to the 27-1-22 antibody 
that had already bound to the column. The column was then rinsed of unbound outer 
membrane proteins using five bed volumes of PBS passed through the column. The 
column was eluted using Sodium Citrate, pH 2.6 in 1ml increments, each combined with 
6 drops of neutralizing buffer (lM Potassium Phosphate dibasic, pH 8.0). These elutions 




The outer membrane proteins, capsular polysaccharides, and lipopolysaccharides 
of Pasteurella haemolytica were purified and stored as previously described. Using the 
Dot-Blot test and the Direct Elisa, the outer membrane proteins were the only surface 
antigens to show reactivity against 27-1 and 27-1-22 ascites-form monoclonal antibody. 
The other surface antigens showed little or no reactivity against the four ascites-form 
monoclonal antibodies. The photograph of the Dot-Blot test result is shown in figure 1, 
followed by the analysis ofthe Direct Elisa produced by the microtiter plate reader in 
figure 2 
Outer Membrane Protein Purification and Analysis 
The outer membrane proteins of Pasteurella haemolytica were purified as 
previously described. Using the BCA analysis, the concentrations of these protein 
preparations were also detennined and recorded. The BCA analysis results for the protein 
purifications are shown in figure 3. SDS-PAGE and Western Blot were used to detennine 
the size and antigenic nature of the proteins. The major antigenic protein was detennined 
to be 18kD in size. Using Western Blot, it was recognized by the 27-1 and 21-1-22 
ascity-fonn monoclonal antibodies. Figure 4 is a list of all the Western Blots and 
SDS-PAGE gels performed upon the purified OMPs. This figure also includes the date of 
each blot or gel, the percentage of polyacrylamide, the concentration of the outer 
membrane proteins, and the primary antibody treatment. The photographs of the Western 
Blots and SDS-PAGE gels are shown in figures 5 through 9. 
After first isolating the 18kD OMP upon the Millipore O.221lm membrane, the 
membrane was sent to Dr. Charles Murphy, University of Tennessee Medical Center, for 
N-terminal sequencing. This sequencing effort indicated that the preparation was not 
clean, so further attempts were made to purify the protein using the method previously 
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described. These efforts were unsuccessful. In another attempt to purify the 18kD 
antigenic OMP, it was decided that affinity chromatography would be used. 
Affinity Chromatography Using Hybridoma-Secreted 27-1-22 Antibody 
Using a viable hybridoma cell culture of the 27-1-22 antibody, a large-scale 
preparation was grown over the course of a few weeks. This supernatant of this 
hybridoma cell culture was filtered by the method previously described. Because the 
supernatant contained the 27-1-22 antibody produced by the hybridoma, it was passed 
over a Rat-Anti Mouse Kappa Light Chain column. The eluent from this affinity 
chromatography was preserved for future use. This eluent was tested for size using an 
SDS-PAGE gel, shown in figure 10. This was also used to prove that the hybridoma cell 
line was viable and secreting antibody. In the figure, the heavy and light chains can be 
seen. To ensure that the column was working efficiently and purifying kappa chain 
antibody, an anti-lambda Western Blot assay was used. The results of this assay are 
shown in figure 11. This shows that the purified antibody was a kappa light chain 
antibody. To test for the binding capability of the purified 27-1-22 antibody to the OMPs, 
an SDS-PAGE gel and Western Blot using the ascity-form and hybridoma-produced 
27-1-22 antibodies as the primary antibody treatments. The results ofthese tests are 
shown in figures 12 and 13. This confirmed that the Kappa light chain column was 
effectively purifying the 27-1-22 antibody. 
Purification of Antigenic 18kD Outer Membrane protein by EAH Sepharose Method 
This affinity chromatography column was constructed as previously described. 
The elutions from these two columns produced very disappointing results. The elutions 
were analyzed at A280, and the results are shown in figure 14. 
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Purification of Antigenic] 8kD Outer Membrane Protein by Kappa Light Chain Method 
This affinity chromatography column was used in the hopes of simultaneously 
purifYing 27-1-22 antibody and outer membrane proteins. The Kappa light chain column 
was used as previously described to purify the 18kD antigenic outer membrane protein. 
The elutions were analyzed at A280, and the results are shown in figure 15. These 
elutions along with the outer membrane proteins that flowed through this affinity 
chromatography column were used in a Western Blot. In this particular blot, the primary 
antibody treatment used was purified 27-1-22 ascity-form monoclonal antibody. The 
secondary antibody treatment used was HRP-Protein G. This Western Blot is shown in 
figure 16. In a further attempt to isolate the antigenic 18kD OMP upon the Millipore 
membrane for N-terminal sequencing, a Western Blot was performed to bind the OMP to 
the membrane and lightly stain the membrane with Coomassie Blue stain. This was done 
using 8% stacking and 10% separating gels. The results of this blot are shown in figure 
17. 
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Figure 1 - Dot-Blot (lmmunoblot) Analysis 
LPS 





Immunoblot showing reactivity of outer membrane proteins with 27-1 and 27-1-22 ascites. 
BSA-bovine serum albumin 
CPS-capsular polysaccharide 
OMP-outer membrane protein 
Lkt-leukotoxin 
LPS-lipopo lysaccharide 
Whole cells-Pasteurella haemolytica whole cells 
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27-/ A 0.031 
27-/ 8 0035 
27-/-22 C 0.045 
27-/-22 D 0.057 
27-2-87 E 0.052 
27-2-87 F 0.062 
27-/8-/03 G 0.351 
27-/8-/03 H 0.338 
~ocehOTide l eukotoxin 
2 3 4 5 
0.018 0.027 0.004 -0.001 
0.017 0.028 0.009 0.003 
0.023 0.038 0.014 0.002 
0.017 0.056 0.013 0.001 
0.021 0037 0.015 0.016 
0.035 0.050 0.022 0.031 
0.280 0.787 0.814 0.823 
0.529 0.784 0.924 1.046 
OM I'ro/eill COD.!u/or I'o/y.me. Rovme Serum A/humin 
6 7 8 9 10 1l 12 
0.001 1095 1009 -0.007 -0.010 -0.012 0.017 
0.003 1953 1695 -0.010 -0.008 -0.011 0.007 
0000 1.964 1978 -0003 -0.007 0.013 0.003 
-0.003 2.105 2039 -0.003 0.149 0000 -0.003 
0.002 0.086 0.069 -0.008 -0.003 -0.005 -0001 
0.017 0.090 0.063 0.005 -0025 0.000 0.004 
0.688 2.144 2.059 0.170 0.171 0.155 0.007 
0.476 2.517 2.388 0.188 0.062 0.016 0.013 
ELISA analysis showing absorbance values for each of the indicated substances. Also 
shown is the high affinity of outer membrane proteins for 27-1 and 27-1-22 ascites, based 
upon absorbance values. 
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Figure 3 - Outer membrane protein purifications 
Outer Membrane Protein Purifications 
Date Purified Concentration (m f! l m I) 
5117/0.0. 0. .580. 
6/2/0. 0. 0..448 
6/2110.0. 0. .925 
711110.0. 2.670. 
7 / 17 / 0.0. 2 .767 
7 /20. / 0.0. 5 .671 
7/24/0.0. 4.788 
7 /26/0.0. 3.4 4 7 
811 / 0. 0. 1 .830. 
8/2 / 0. 0. 2 .5 J 0. 
Each outer membrane protein purification concentration is listed by date 
Figure 4 - List of Western Blots and SDS-PAGE gels performed 
We.wmllas 1ft! sa;..PA(E Gds forlUer M:nimne PtrXtim 
~ frteriPeifcmure Te!JTw ~ Sermiirg% QM'Cin:£rtroJia1(mil7ii 
5 12!7I9)WSfmIb 4"10 10'/. 0..338 !Ill o..184 







1 Plo 0..338 !Ill 0.327 
IP/.o.338, 0..327, !Ill 0..514 
15% 0..327 !Ill 0..514 
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PrinuyArtilxxfv T T"f!l1rrFnl q-Stan 
21-1, 27-1-Z2, !Ill Oxrm;sie Slain 
27-1, 27-I-Z2, !IlIOxrm;sieSlain 
27-1, 27-I-Z2, !Ill Oxrm;sie Slain 
~Stai1 
27-1, 27-I-Z2, !Ill Gxnm;ie Slain 
Figure 5 - Western blot of outer membrane proteins 






- 21.5kD - ---
Z7-( 
114: 91 12/9719' 
Western blot showing an 18kD outer membrane protein binding to 27-1 and 27-1-22 
ascites. CB refers to Coommassie blue staining of the membrane. 
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Figure 6 - Western Blot of outer membrane proteins 
Western blot showing an 18kD outer membrane protein binding to 27-1 and 27-1-22 
ascites. CB refers to Coomassie blue staining of the membrane. 
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Figure 7 - Western blot of outer membrane proteins 
Western Blot showing an 18kD outer membrane protein binding to 27-1 and 27-1-22 
ascites. CB refers to Coomassie blue staining of the membrane. 
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Figure 8 - SDS-PAGE gel of outer membrane proteins 
SDS-PAGE gel showing the outer membrane protein purification separated according to 
size. The protein of interest is shown to be 18kD in size. 
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Figure 9 - Western Blot of outer membrane proteins 
Western Blot showing an 18kD outer membrane protein binding to 27-1 and 27-1-22 
ascites. CB refers to Coomassie blue staining of the membrane. 
32 




The heavy and light chains can be visualized at 46kD and 20kD_ This gel was used to 
prove that the hybridoma cell line was viable and actively secreting antibody_ 
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Western blot showing that the 27-1-22 was not a lambda light chain antibody. 
Anti-lambda purification was the primary antibody treatment. Reactivity of the ascites is 
most likely due to the presence of fetal bovine serum. 
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Figure 12 - SDS PAGE gel of outer membrane proteins 
SDS-PAGE gel of outer membrane proteins, showing the protein of interest to be 18kD in 
SIZe. 
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Figure 13 - Western blot of outer membrane proteins 
Western blot showing binding of18kD outer membrane proteins to 27-1-22 ascites, 
eluent, and unpurified supernatant. 
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Figure 14 







Absorbance values for elution of ascity and antibody from the EAH Sepharose affinity 
column 
Figure 15 







Absorbance values for dual elution of outer membrane protein and 27-1-22 antibody from 
the Kappa Light Chain affinity column. 
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Figure 16 - Western Blot of eluent from dual elution method 
column 
elution 
This Western Blot shows binding of outer membrane proteins, in both the elution and 
column flow through, binding to 27-1-22 ascites. 
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Figure 17 - Light Coomassie Stain of outer membrane proteins and the 






This light Coomassie stain shows the 18kD outer membrane protein and the size 




After purification of outer membrane proteins, capsular polysaccharide, and 
lipopolysaccharide, the outer membrane proteins were the only surface antigens to react 
with ascites-form monoclonal antibodies 27-1 and 27-1-22 in Direct ELISA and Dot-Blot 
tests. Therefore, study was concentrated upon outer membrane proteins and their value 
as surface antigens of Pasteurella haemolytica AI. In order to further study the OMPs, 
many protein purifications were made according to the method previously stated. 
Outer Membrane Protein Analysis 
The concentration of each protein purification was determined using the BCA 
analysis. The primary mode of analysis for the OMPs was the Western Blot and SDS-
PAGE. These two tests allowed for the discovery of the size of the major antigenic 
protein and its respective antibody. From the results obtained it was decided that SDS-
PAGE gels should be 8% stacking and 15% separating for optimal migration of the 18kD 
OMP of P. haemolytica. Variation in the concentration of the OMP loaded onto the gel 
or Western Blot seemed to have little effect upon the results obtained. The major 
antigenic protein was found to be 18kD in size and reactive against 27-1 and 27-1-22 
ascites-form monoclonal antibodies, as shown by the photographs of the blots and gels. 
Therefore, the rest of the study was thereafter concentrated upon further purifying this 
particular OMP and isolating it for N-terminal sequencing, so as to more specifically 
characterize this specific antigenic protein. 
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Because the first sequencing effort by Dr. Charles Murphy was unsuccessful, 
further attempts were made to purify the protein using the methods previously described. 
Because these efforts were not effective, it was decided that affinity chromatography was 
necessary to specifically isolate the antigenic protein of interest. 
Purification and Analysis of 27 -1-22 Antibody 
Although the protein antigen bound to both the 27-1 and 27-1-22 type antibodies, 
the 27-1-22 type antibody was chosen for further study because of its availability in the 
form of a hybridoma cell culture. This antibody type was grown in large quantities from 
a viable hybridoma cell culture previously produced by Don Gerbig (18). The eluent 
derived from the use ofthe Rat-Anti Mouse Kappa Light Chain column was found to 
contain both heavy and light chains, demonstrating that antibody was purified using the 
column (figure 10). This also demonstrated that the hybridoma cell line was in fact 
secreting antibody. However, this was not conclusive because of the presence oftetal 
bovine serum in the hybridoma supernatant. Figure 11 was used to prove that the 27-1-
22 antibody was a kappa chain antibody. This test was necessary because ofthe low 
elution yields produced by the Kappa chain affmity column. The Western Blot shown in 
figure 11 identified no lambda light chain antibodies using the anti-lambda primary 
antibody treatment. The problems with purification of significant levels of the 27-1-22 
antibody were thought to be linked to problems with the pH of the elution buffer or low 
levels of antibody production by the hybridoma cell line. 
Figures 12 and 13 show attempts to determine if the antibody being purified with 
the Kappa light chain affmity column was reactive with the purified outer membrane 
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proteins of interest. The SDS-PAGE gel was performed to test the quality of the OMP 
samples and to use for comparison with the results of the Western Blot. From the SDS-
PAGE gel, it was evident that the protein of interest had not suffered degradation. 
Column-purified 27-1-22 was also loaded onto this gel, but produced no visible bands of 
sizes indicating the presence of heavy or light chain immunoglobulins. The Western Blot 
was designed to test for reactivity of the outer membrane proteins with the purified 27-1-
22 antibody. From this test, it was evident that at least some antibody was being purified 
by the column, since there was clear reactivity between the 18kD OMP and the column-
purified 27-1-22 antibody. 
Purification and Analysis of Antigenic 18kD OMP using EAR Sepharose Method 
The elutions from the two EAR Sepharose affinity chromatography columns 
produced disappointing results, as shown in figure 14. Reasons for the failure of these 
two affmity columns could include such reasons as ineffective binding of the antibody to 
the Sepharose 4B gradient, ineffective capture of the antigenic OMP by the 27-1-22 
antibody, or failure of the binding or elution buffer to function properly. Because of the 
failure of this attempt and its time-consuming nature, this method was abandoned for the 
Kappa light chain method. 
Purification and Analysis of Antigenic 18kD OMP using Kappa Light Chain Method 
In the hopes of simultaneously purifying the 27-1-22 antibody and OMP, this 
method was employed. The analysis of the elution is shown in figure 15. The numbers 
produced by the spectrophotometry seemed to indicate positive results. Therefore, it was 
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hoped that this method has succeeded. If this method had worked as planned, pure 18kD 
OMP would have been isolated for N-tenninal amino acid sequencing. Although this 
method was more effective than the EAH Sepharose method, it was not effective enough 
in its ability to purify the 18kD OMP. These results are shown in figures 16 and 17 in the 
Western Blot photographs. Figure 16 shows that a higher concentration of the 18kD 
OMP was found in the column flow-through than in the actual elution. Some of this 
could have been due to incomplete pH neutralization of the elutions. One possible 
solution to this would have been dialysis, but it was feared that this would lead to loss of 
the protein of interest because of its small size. Although the OMP was visualized using 
the light Coomassie stain in figure 16, it did not seem that this band was distinct enough 
or clear enough for N-terminal sequencing attempts. Figure 17 shows another Western 
Blot using light Coomassie stain in which the OMP127-1-22 joint elution was analyzed 
for size and apparent concentration according to the location and brightness of the protein 
bands. Again, in this case, it seems that pH problems continue to hinder the effective 
migration of the sample down the length of the gel. Perhaps if time had permitted, more 
protein preparations would have been tested using affmity chromatography in 
conjunction with the 27-1-22 antibody. However, time was limiting and the failed results 
were discouraging. 
Although attempts at using affmity chromatography were not as successful as one 
might have hoped, they have confirmed that the 27-1-22 is a Kappa light chain antibody 
and the 18kD OMP does bind to it when tested by immunoblot. A possible way to 
improve the results of these experiments might be to find a way to increase the affinity of 
the 27-1-22 antibody to the Kappa light chain affmity column and then couple this more 
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concentrated eluent to the EAR Sepharose 4B column. This might be more effective in 
purifYing the 18kD outer membrane protein. Perhaps more successful results could be 
obtained by the use of different elution and binding buffers that would produce optimal 
binding and elution of the protein or antibody of interest. Other methods of purification, 
such as HPLC, 2D protein gels, or ion-exchange chromatography, might also be more 
effective. Because the 18kD OMP is antigenic, it deserves more study as a possible 
vaccine component. However, before more study can be done in this area, the protein 
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